Merck sues U.S. government over plan to negotiate Medicare drug prices, claiming "extortion"
CBSN
Drugmaker Merck is suing the U.S. government over its plan to allow Medicare to negotiate prices for a handful of drugs, calling it "extortion."
The plan, part of the 2022 Inflation Reduction Act, is expected to save taxpayers billions of dollars on common drugs the government pays for. The law directs the Center for Medicare and Medicaid Services to select 10 drugs with no generic or biosimilar equivalents to be subject to government price negotiation. (The list will eventually expand to 20 drugs.)
In its lawsuit, filed on Tuesday in federal court in the District of Columbia, Merck called the program "a sham" that "involves neither genuine 'negotiations' nor real 'agreements.'" Instead, the pharmaceutical firm said the U.S. Department of Health and Human Services selects drugs to be included and then dictates a discount, threatening drugmakers with "a ruinous daily excise tax" if they refuse the conditions.

The two rounds of indirect talks between the U.S. and Iran have produced unique proposals addressing Iran's nuclear program — its enrichment capabilities and supply of highly enriched uranium — and how to make a deal that's economically beneficial to both countries, diplomatic sources tell CBS News.

Truckee, California — Survivors tried to unbury their friends when an avalanche struck a group of backcountry skiers near Lake Tahoe in Northern California earlier this week, according to new harrowing details from a local sheriff's official. The avalanche, the deadliest in California history, killed at least eight people and left a ninth person missing. In:

Washington — Abigail Shry's verbal threats against public officials have been racist, violent and detailed. Her targets have included a federal judge in Washington, a Democrat in the House and the Texas Capitol. She allegedly once said she would "annihilate" the Texas government in an "armed attack" that would be more violent than the Jan. 6 insurrection.










